Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intravenous immunoglobulin: new clinical applications.

R W Steele1, A W Burks, L W Williams

  • 1Department of Pediatrics, University of Arkansas for Medical Sciences.

Annals of Allergy
|February 1, 1988
PubMed
Summary

Intravenous immunoglobulin (IVIG) is approved for specific conditions like antibody deficiencies and ITP. Further research is needed for other autoimmune diseases, and individualized dosing is crucial due to varied guidelines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early-life gut microbiome and egg allergy.

Allergy·2018
Same author

Integrative transcriptomic analysis reveals key drivers of acute peanut allergic reactions.

Nature communications·2017
Same author

Component-resolved analysis of IgA, IgE, and IgG4 during egg OIT identifies markers associated with sustained unresponsiveness.

Allergy·2016
Same author

Utility of component analyses in subjects undergoing sublingual immunotherapy for peanut allergy.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2015
Same author

Effects of a pre-existing food allergy on the oral introduction of food proteins: findings from a murine model.

Allergy·2014
Same author

Allergen immunotherapy: a new semantic framework from the European Academy of Allergy and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report.

Allergy·2013

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Three intravenous immunoglobulin (IVIG) preparations are commercially available.
  • No single IVIG product demonstrates a therapeutic advantage over others.
  • Current approved uses include antibody deficiency syndromes and idiopathic thrombocytopenic purpura.

Purpose of the Study:

  • To review the current approved and potential therapeutic applications of IVIG.
  • To highlight the need for further research in specific autoimmune conditions.
  • To emphasize the importance of individualized dosing and literature review for IVIG therapy.

Main Methods:

  • Review of existing literature and clinical trial data on IVIG efficacy.
  • Analysis of approved indications versus suggested benefits from open studies.
  • Examination of variability in reported IVIG dosages and infusion intervals.

Main Results:

  • IVIG is proven effective for Kawasaki disease and preventing specific infections (sepsis, CMV) in immunocompromised individuals.
  • Open studies suggest potential benefits for neonatal sepsis, chronic Epstein-Barr virus, and autoimmune diseases, requiring further validation.
  • Significant adverse reactions to IVIG are rare, but high cost limits its widespread use.

Conclusions:

  • IVIG is an established therapy for specific immune deficiencies and hematologic disorders.
  • Further rigorous studies are necessary to confirm IVIG's efficacy in various autoimmune conditions.
  • Physicians must individualize IVIG treatment based on current evidence and patient-specific factors, considering the high cost.

Related Experiment Videos